The most notable companies in this group are AstraZeneca PLC (NASDAQ:AZN).
The investment seeks to provide investment results that correlate, before fees and expenses, to the performance of 125% of the fair value of the STOXX Europe 50® Index.
The fund employs as its investment strategy a program of investing in the common stock of companies that are generally within the capitalization range of the underlying index and derivative instruments. It will invest at least 80% of its net assets, plus any borrowings for investment purposes, in securities of companies in the underlying index and derivatives and other instruments whose performance is expected to correspond to that of the underlying index. The fund is non-diversified.
The average market capitalization across the Rydex Europe 1.25x Strategy A MF is 279.3B. The market cap for tickers in the group ranges from 201.42B to 546.76B. NVO holds the highest valuation in this group at 546.76B. The lowest valued company is AZN at 201.42B.
The average weekly volume growth across all stocks in the Rydex Europe 1.25x Strategy A MF was -21%. For the same stocks of the MF, the average monthly volume growth was -29% and the average quarterly volume growth was 27%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 44
P/E Growth Rating: 49
Price Growth Rating: 48
SMR Rating: 62
Profit Risk Rating: 34
Seasonality Score: -32 (-100 ... +100)